PL434198A1 - Związki do leczenia lub diagnostyki COVID-19 - Google Patents

Związki do leczenia lub diagnostyki COVID-19

Info

Publication number
PL434198A1
PL434198A1 PL434198A PL43419820A PL434198A1 PL 434198 A1 PL434198 A1 PL 434198A1 PL 434198 A PL434198 A PL 434198A PL 43419820 A PL43419820 A PL 43419820A PL 434198 A1 PL434198 A1 PL 434198A1
Authority
PL
Poland
Prior art keywords
covid
diagnosis
compounds
treatment
prevention
Prior art date
Application number
PL434198A
Other languages
English (en)
Inventor
Marcin Drąg
Wioletta RUT
Original Assignee
Politechnika Wrocławska
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Politechnika Wrocławska filed Critical Politechnika Wrocławska
Priority to PL434198A priority Critical patent/PL434198A1/pl
Priority to EP21752770.4A priority patent/EP4161497A1/en
Priority to PCT/PL2021/050037 priority patent/WO2021246886A1/en
Publication of PL434198A1 publication Critical patent/PL434198A1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Przedmiotem zgłoszenia są związki do stosowania w leczeniu, profilaktyce lub diagnostyce COVID-19.
PL434198A 2020-06-04 2020-06-04 Związki do leczenia lub diagnostyki COVID-19 PL434198A1 (pl)

Priority Applications (3)

Application Number Priority Date Filing Date Title
PL434198A PL434198A1 (pl) 2020-06-04 2020-06-04 Związki do leczenia lub diagnostyki COVID-19
EP21752770.4A EP4161497A1 (en) 2020-06-04 2021-06-04 Compounds for the treatment or diagnosis of covid-19
PCT/PL2021/050037 WO2021246886A1 (en) 2020-06-04 2021-06-04 Compounds for the treatment or diagnosis of covid-19

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL434198A PL434198A1 (pl) 2020-06-04 2020-06-04 Związki do leczenia lub diagnostyki COVID-19

Publications (1)

Publication Number Publication Date
PL434198A1 true PL434198A1 (pl) 2021-12-06

Family

ID=77300961

Family Applications (1)

Application Number Title Priority Date Filing Date
PL434198A PL434198A1 (pl) 2020-06-04 2020-06-04 Związki do leczenia lub diagnostyki COVID-19

Country Status (3)

Country Link
EP (1) EP4161497A1 (pl)
PL (1) PL434198A1 (pl)
WO (1) WO2021246886A1 (pl)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9597274B2 (en) * 2015-06-17 2017-03-21 Avon Products, Inc. Peptides and their use in the treatment of skin

Also Published As

Publication number Publication date
EP4161497A1 (en) 2023-04-12
WO2021246886A1 (en) 2021-12-09

Similar Documents

Publication Publication Date Title
CO2017006230A2 (es) Compuestos de n-((het)arilmetil)-heteroaril-carboxamidas como inhibidores de calicreína plasmática
ZA201906832B (en) Novel psma-binding agents and uses thereof
JOP20200209A1 (ar) مثبطات cd73
MA41013B1 (fr) Compositions comprenant des souches bactériennes
BR112015013123A2 (pt) inibidores de beta-lactamase
EA201390609A1 (ru) ПРОИЗВОДНЫЕ ГИДАНТОИНА, ПОЛЕЗНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ Kv3-КАНАЛОВ
GEP20227406B (en) Chromane monobactam compounds for the treatment of bacterial infections
EA201891377A1 (ru) ПРИМЕНЕНИЕ МОДУЛЯТОРОВ КАНАЛОВ Kv3.1/Kv3.2/Kv3.3 ДЛЯ ЛЕЧЕНИЯ БОЛИ
EA201891644A1 (ru) Антибактериальные соединения и их применение
AU2015267099A8 (en) Use of eribulin in the treatment of cancer
MD3615544T2 (ro) Compuși antitumorali
MX2017013047A (es) Tratamiento de dolor.
UY38352A (es) Inhibidores de integrina alfavbeta6
MX2021000542A (es) Apirasas solubilizadas, metodos y usos.
ZA202106519B (en) Caspase inhibitors and methods of use thereof
EA202090266A1 (ru) Ингибиторы mpo для применения в медицине
PH12021550121A1 (en) Methods of treating hfpef employing dapagliflozin and compositions comprising the same
BR112018012126A2 (pt) ?adjuvante, método para prevenir e/ou tratar uma doença autoimune, e, uso de um adjuvante?
PL434198A1 (pl) Związki do leczenia lub diagnostyki COVID-19
CL2022000067A1 (es) Composiciones para el tratamiento de la pérdida del cabello
WO2018211324A8 (en) Prodrugs for the treatment of disease
CY1124851T1 (el) Νεες ενωσεις
MX2021002444A (es) Compuestos y metodos para el tratamiento de infecciones fungicas.
EA202190045A1 (ru) Составы/композиции, содержащие ибрутиниб
EA202193121A1 (ru) Лечение рака